This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

This study has been completed.
Information provided by (Responsible Party):
Wenrong Huang, Chinese PLA General Hospital Identifier:
First received: July 4, 2012
Last updated: April 16, 2014
Last verified: April 2014

Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile patients with neutropenia of high risk. In china, the data of piperacillin/tazobactam for febrile neutropenia after hematopoietic stem cell transplantation is very limited.

The current study will evaluate the efficacy of piperacillin/tazobactam compared with imipenem/cilastatin for febrile neutropenia after transplantation.

Condition Intervention
Febrile Neutropenia Hematopoietic Stem Cell Transplantation Drug: Piperacillin-tazobactam combination product Drug: Imipenem

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Wenrong Huang, Chinese PLA General Hospital:

Primary Outcome Measures:
  • Clinical success rate. [ Time Frame: 3 weeks after beginning of empirical therapy ]
    Resolve of clinical symptoms and signs, without change of therapy.

Secondary Outcome Measures:
  • Microbiologic success rate [ Time Frame: 3 weeks after beginning of empirical therapy ]

    Microbiologic success includes eradication, suspected eradication, and super-infection.

    1. Eradication or Presumed eradication: the baseline pathogens no longer present on the culture performed after completion of treatment. If no way to collect biologic sample(s) after treatment;, e.g. sputum, a presumed eradication will be concluded
    2. No eradication: one or more baseline pathogens were persistent
    3. Relapse: the baseline pathogens transient absence reappeared during the therapy
    4. Alternative: the baseline pathogens were eradicated, but new ones appeared without any clinical signs and symptoms
    5. Re-infection: the baseline pathogens were eradicated, but new ones appeared with clinical signs and symptoms.

  • Adverse effect [ Time Frame: 3 weeks after beginning of empirical therapy ]
    The number of patients developed unexpected medical information at the 3 weeks after beginning of empirical therapy.

  • Cost of drug and therapy [ Time Frame: 3 weeks after beginning of empirical therapy ]

Enrollment: 123
Study Start Date: November 2012
Study Completion Date: April 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: piperacillin/tazobactam Drug: Piperacillin-tazobactam combination product
4.5g q6h, 5-10 days
Other Name: Tazocin
Active Comparator: imipenem/cilastatin Drug: Imipenem
0.5g q6h, 5-10 days
Other Name: Tienam

Detailed Description:
  1. Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room after transplantation.
  2. Randomize the febrile patients into 2 groups.
  3. Therapy group receive piperacillin/tazobactam, 4.5g q6h iv. Control group receive imipenem/cilastatin, 0.5g q6h. Duration will be 5-10 days.

Ages Eligible for Study:   13 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 13-65 years
  • received Autologous or Allogeneic hematopoietic stem cell transplantation.
  • ECOG score 0-1.
  • ICF is available.

Exclusion Criteria:

  • Allergic to any therapy drug.
  • Documented infection before neutropenia.
  • Renal dysfunction.
  • Suffering from central nervous system or mental disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01714570

China, Beijing
Chinese PLA general hospital
Beijing, Beijing, China, 100853
Sponsors and Collaborators
Chinese PLA General Hospital
Principal Investigator: wenrong huang, Doctor Employee
  More Information

Responsible Party: Wenrong Huang, Associate director, Hematology, Chinese PLA General hospital, Chinese PLA General Hospital Identifier: NCT01714570     History of Changes
Other Study ID Numbers: PTZ-20120702
Study First Received: July 4, 2012
Last Updated: April 16, 2014

Additional relevant MeSH terms:
Leukocyte Disorders
Hematologic Diseases
Body Temperature Changes
Signs and Symptoms
Penicillanic Acid
Piperacillin, tazobactam drug combination
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017